# Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

> **NCT05180773** · PHASE4 · RECRUITING · sponsor: **Dennis M. McNamara, MD, MS** · enrollment: 250 (estimated)

## Conditions studied

- Peripartum Cardiomyopathy, Postpartum

## Interventions

- **DRUG:** Bromocriptine
- **DRUG:** Placebo
- **DRUG:** Guideline Directed Medical Therapy for Heart Failure (GDMT)
- **DRUG:** Rivaroxaban
- **DRUG:** Second Placebo

## Key facts

- **NCT ID:** NCT05180773
- **Lead sponsor:** Dennis M. McNamara, MD, MS
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-27
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05180773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05180773, "Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT05180773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*